Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

Similar articles for PubMed (Select 15699481)

1.

Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors.

Kortmansky J, Shah MA, Kaubisch A, Weyerbacher A, Yi S, Tong W, Sowers R, Gonen M, O'reilly E, Kemeny N, Ilson DI, Saltz LB, Maki RG, Kelsen DP, Schwartz GK.

J Clin Oncol. 2005 Mar 20;23(9):1875-84. Epub 2005 Feb 7.

2.

The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial.

Lara PN Jr, Mack PC, Synold T, Frankel P, Longmate J, Gumerlock PH, Doroshow JH, Gandara DR.

Clin Cancer Res. 2005 Jun 15;11(12):4444-50.

3.

Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study.

Hotte SJ, Oza A, Winquist EW, Moore M, Chen EX, Brown S, Pond GR, Dancey JE, Hirte HW.

Ann Oncol. 2006 Feb;17(2):334-40. Epub 2005 Nov 10.

4.

Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors.

Jimeno A, Rudek MA, Purcell T, Laheru DA, Messersmith WA, Dancey J, Carducci MA, Baker SD, Hidalgo M, Donehower RC.

Cancer Chemother Pharmacol. 2008 Mar;61(3):423-33. Epub 2007 Apr 12.

5.

A phase I trial of daily oral 4'- N -benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignancies.

Eder JP Jr, Garcia-Carbonero R, Clark JW, Supko JG, Puchalski TA, Ryan DP, Deluca P, Wozniak A, Campbell A, Rothermel J, LoRusso P.

Invest New Drugs. 2004 Apr;22(2):139-50.

PMID:
14739662
6.
7.

Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms.

Sausville EA, Arbuck SG, Messmann R, Headlee D, Bauer KS, Lush RM, Murgo A, Figg WD, Lahusen T, Jaken S, Jing X, Roberge M, Fuse E, Kuwabara T, Senderowicz AM.

J Clin Oncol. 2001 Apr 15;19(8):2319-33.

PMID:
11304786
8.

Phase I and pharmacokinetic study of 7-hydroxystaurosporine and carboplatin in advanced solid tumors.

Edelman MJ, Bauer KS Jr, Wu S, Smith R, Bisacia S, Dancey J.

Clin Cancer Res. 2007 May 1;13(9):2667-74.

9.

Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer.

Schilsky RL, Hohneker J, Ratain MJ, Janisch L, Smetzer L, Lucas VS, Khor SP, Diasio R, Von Hoff DD, Burris HA 3rd.

J Clin Oncol. 1998 Apr;16(4):1450-7.

PMID:
9552051
10.

UCN-01 (7-hydroxystaurosporine) enhances 5-fluorouracil cytotoxicity through down-regulation of thymidylate synthetase messenger RNA.

Abe S, Kubota T, Otani Y, Furukawa T, Watanabe M, Kumai K, Kitajima M.

Jpn J Cancer Res. 2000 Nov;91(11):1192-8.

PMID:
11092986
11.

A phase I, dose-finding study of irinotecan (CPT-11) short i.v. infusion combined with fixed dose of 5-fluorouracil (5-FU) protracted i.v. infusion in adult patients with advanced solid tumours.

Sastre J, Paz-Ares L, Carcas A, Alfonso R, Grávalos C, Frías J, Guerra P, Pronk L, Cortés-Funes H, Díaz-Rubio E.

Cancer Chemother Pharmacol. 2005 May;55(5):453-60. Epub 2004 Oct 26.

PMID:
15818508
12.

A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas.

Kummar S, Gutierrez ME, Gardner ER, Figg WD, Melillo G, Dancey J, Sausville EA, Conley BA, Murgo AJ, Doroshow JH.

Cancer Chemother Pharmacol. 2010 Jan;65(2):383-9. doi: 10.1007/s00280-009-1154-y. Epub 2009 Nov 6.

14.

A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies.

Fracasso PM, Williams KJ, Chen RC, Picus J, Ma CX, Ellis MJ, Tan BR, Pluard TJ, Adkins DR, Naughton MJ, Rader JS, Arquette MA, Fleshman JW, Creekmore AN, Goodner SA, Wright LP, Guo Z, Ryan CE, Tao Y, Soares EM, Cai SR, Lin L, Dancey J, Rudek MA, McLeod HL, Piwnica-Worms H.

Cancer Chemother Pharmacol. 2011 Jun;67(6):1225-37. doi: 10.1007/s00280-010-1410-1. Epub 2010 Aug 8.

15.

A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial.

Li T, Christensen SD, Frankel PH, Margolin KA, Agarwala SS, Luu T, Mack PC, Lara PN Jr, Gandara DR.

Invest New Drugs. 2012 Apr;30(2):741-8. doi: 10.1007/s10637-010-9562-8. Epub 2010 Oct 22.

16.

Modulation of cell cycle progression in human tumors: a pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850).

Perez RP, Lewis LD, Beelen AP, Olszanski AJ, Johnston N, Rhodes CH, Beaulieu B, Ernstoff MS, Eastman A.

Clin Cancer Res. 2006 Dec 1;12(23):7079-85.

17.

Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome.

Gojo I, Perl A, Luger S, Baer MR, Norsworthy KJ, Bauer KS, Tidwell M, Fleckinger S, Carroll M, Sausville EA.

Invest New Drugs. 2013 Oct;31(5):1217-27. doi: 10.1007/s10637-013-9937-8. Epub 2013 Feb 27.

18.

Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors.

Adjei AA, Reid JM, Diasio RB, Sloan JA, Smith DA, Rubin J, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Atherton P, Ames MM, Erlichman C.

J Clin Oncol. 2002 Mar 15;20(6):1683-91.

PMID:
11896120
19.

Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil.

Baker SD, Diasio RB, O'Reilly S, Lucas VS, Khor SP, Sartorius SE, Donehower RC, Grochow LB, Spector T, Hohneker JA, Rowinsky EK.

J Clin Oncol. 2000 Feb;18(4):915-26.

PMID:
10673535
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk